Cero Therapeutics Holdings Inc (CERO)

$5.28 -0.11 (-2.04%)
Market Cap 6.36M
Revenue (ttm) 0.00
Net Income (ttm) -8.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,200
Avg Vol 161,038
Day's Range N/A - N/A
Shares Out 1.21M
Stochastic %K 54%
Beta 0.41
Analysts Strong Sell
Price Target $30.00

Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Industry: Biotechnology
Sector: Healthcare
Phone: (650) 407-2376
Address:
201 Haskins Way, Suite 230, South San Francisco, United States
Zerodegree00
Zerodegree00 Oct. 4 at 6:46 AM
$CERO
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:31 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $ONCO $CHNR $CERO $ARTL
0 · Reply
MaxTradez
MaxTradez Oct. 3 at 1:23 AM
$PAVS Now my top position. Added a bunch more today. Also have starters on $CETX and $CERO due to pump again soon $ABVE Celebrating with a tuno sandwich!
1 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:35 AM
$CBIO $ONCO $CHNR $CERO \
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:35 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CBIO $ONCO $CHNR $CERO
0 · Reply
globaldaytraderzzz
globaldaytraderzzz Oct. 2 at 4:29 PM
$CERO down fm 2600 in COVID to $5 💥💥
0 · Reply
globaldaytraderzzz
globaldaytraderzzz Oct. 2 at 3:58 PM
$CERO
0 · Reply
Love_To_Learn
Love_To_Learn Oct. 2 at 11:31 AM
$CERO u have an update pending
1 · Reply
Gravy_Trains
Gravy_Trains Oct. 2 at 12:51 AM
$PAVS the gravy will be served soon. Holding for a $3 run. All those insiders want their gravy too $YAAS Close watch for bottom. $CERO Its due for a launch $OPEN Holding and bidding for more
0 · Reply
Chinoobaby
Chinoobaby Oct. 1 at 9:35 AM
$CERO holy cow! I see this hitting over 20 today 💥
2 · Reply
Latest News on CERO
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Sep 22, 2025, 9:15 AM EDT - 12 days ago

CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort

Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 25 days ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

SMMT

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

Sep 9, 2025, 8:15 AM EDT - 25 days ago

CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

Sep 8, 2025, 8:45 AM EDT - 26 days ago

CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

Sep 5, 2025, 8:00 AM EDT - 4 weeks ago

CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Jul 31, 2025, 8:10 AM EDT - 2 months ago

CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

Jul 8, 2025, 12:00 AM EDT - 3 months ago

Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

Jun 23, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

Jun 17, 2025, 8:15 AM EDT - 3 months ago

CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

Jun 11, 2025, 9:10 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

Jun 6, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

Jun 2, 2025, 9:05 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

May 30, 2025, 8:15 AM EDT - 4 months ago

CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

May 8, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 30, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 25, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 24, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

Apr 22, 2025, 8:15 AM EDT - 5 months ago

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Apr 10, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Apr 9, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

Mar 31, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

Mar 27, 2025, 8:15 AM EDT - 6 months ago

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

Mar 19, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

Mar 13, 2025, 8:15 AM EDT - 7 months ago

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

Mar 6, 2025, 8:15 AM EST - 7 months ago

CERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational Assays

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

Mar 5, 2025, 8:15 AM EST - 7 months ago

CERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14

CERo Therapeutics Holdings, Inc. Highlights Progress

Feb 6, 2025, 8:15 AM EST - 8 months ago

CERo Therapeutics Holdings, Inc. Highlights Progress

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Feb 5, 2025, 8:00 PM EST - 8 months ago

CERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

Dec 6, 2024, 9:00 AM EST - 10 months ago

CERo Therapeutics, Inc. Appoints Chris Ehrlich CEO

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Nov 15, 2024, 8:45 AM EST - 11 months ago

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

Nov 11, 2024, 8:15 AM EST - 11 months ago

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Provides Corporate Update

Oct 21, 2024, 9:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Oct 2, 2024, 9:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

Sep 25, 2024, 2:49 PM EDT - 1 year ago

Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Sep 25, 2024, 9:17 AM EDT - 1 year ago

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

Jul 18, 2024, 7:55 AM EDT - 1 year ago

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

ASLN

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

Jun 13, 2024, 8:15 AM EDT - 1 year ago

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

May 15, 2024, 8:00 AM EDT - 1 year ago

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Mar 7, 2024, 7:00 AM EST - 1 year ago

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

Feb 14, 2024, 4:48 PM EST - 1 year ago

Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Jun 5, 2023, 8:00 AM EDT - 2 years ago

CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Dec 6, 2022, 9:18 PM EST - 3 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders

Zerodegree00
Zerodegree00 Oct. 4 at 6:46 AM
$CERO
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 7:31 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $ONCO $CHNR $CERO $ARTL
0 · Reply
MaxTradez
MaxTradez Oct. 3 at 1:23 AM
$PAVS Now my top position. Added a bunch more today. Also have starters on $CETX and $CERO due to pump again soon $ABVE Celebrating with a tuno sandwich!
1 · Reply
MoonCowBoy
MoonCowBoy Oct. 3 at 12:35 AM
$CBIO $ONCO $CHNR $CERO \
0 · Reply
1Spartantrade1
1Spartantrade1 Oct. 2 at 6:35 PM
Massive merger news 3 days ago on NITO! NITO has a low share count like TTNP (BTTC) does. TTNP ran 400% today. Can NITO also run 400%? Make sure to take profits. Lets see if NITO halts up today when people realize. $CBIO $ONCO $CHNR $CERO
0 · Reply
globaldaytraderzzz
globaldaytraderzzz Oct. 2 at 4:29 PM
$CERO down fm 2600 in COVID to $5 💥💥
0 · Reply
globaldaytraderzzz
globaldaytraderzzz Oct. 2 at 3:58 PM
$CERO
0 · Reply
Love_To_Learn
Love_To_Learn Oct. 2 at 11:31 AM
$CERO u have an update pending
1 · Reply
Gravy_Trains
Gravy_Trains Oct. 2 at 12:51 AM
$PAVS the gravy will be served soon. Holding for a $3 run. All those insiders want their gravy too $YAAS Close watch for bottom. $CERO Its due for a launch $OPEN Holding and bidding for more
0 · Reply
Chinoobaby
Chinoobaby Oct. 1 at 9:35 AM
$CERO holy cow! I see this hitting over 20 today 💥
2 · Reply
Washingtonstate
Washingtonstate Sep. 30 at 12:24 PM
$CERO
0 · Reply
PrimeTradingCorp
PrimeTradingCorp Sep. 29 at 12:07 AM
$PAVS low float rocket! $1.15 post-market, Ichimoku bullish, volume growth. $2.50 GAP fill—buy now! $YAAS might be a play this week $VMAR Bids are in $CERO Due for another run
1 · Reply
ChipPetey11
ChipPetey11 Sep. 28 at 4:49 PM
$CERO
0 · Reply
LegendaryCharts
LegendaryCharts Sep. 28 at 12:23 PM
$PAVS Nice breakout friday night, looks like they sending this next, top watch for me $EPOW 1gw battery pack announced $CERO new patent also $TNXP got that FDA lisiting , bullish
0 · Reply
Gravy_Trains
Gravy_Trains Sep. 27 at 7:34 PM
$PAVS 📈soaring after hours to $1.20! Today’s volume surge, RSI 75 climbing. Paranovus AI entertainment rocket—$3 🎯 $CERO Looks due again. I may grab starter $CETX Haven’t watched, damn it’s cooked $FLUX Haven’t sold a share. Holding long
1 · Reply
StockHounding
StockHounding Sep. 27 at 2:33 AM
$CERO $LQR $PAVS $RYOJ has paid twice and PAVS will pay twice as much. We in it to win it.
0 · Reply
Gravy_Trains
Gravy_Trains Sep. 27 at 2:21 AM
$CERO $LQR $PAVS $RYOJ 👇 Wow! I’ve been giving you guys bangers. PAVS 🚀 Monday squeeze in play CERO hasn’t run yet but news was good LQR AND RYOJ Banked!! 🎉
0 · Reply
2old2beBroke
2old2beBroke Sep. 26 at 9:25 PM
$CERO $GYRO 👀 dumb low float stupid high 52week high . I kno they broke af but when that ever stopped this group of bulls 🤔🤷🏻‍♂️🫣
0 · Reply
Trader_Tom
Trader_Tom Sep. 26 at 8:39 PM
$CERO patent news Also, watching $APLT $OSRH $JFBR
1 · Reply
globaldaytraderzzz
globaldaytraderzzz Sep. 26 at 7:59 PM
$CERO watch
0 · Reply
PatentGrants
PatentGrants Sep. 26 at 7:57 PM
$CERO Cero Therapeutics has received a decision to grant European patent number EP4376874 titled "CHIMERIC TIM4 RECEPTORS AND USES THEREOF (FOR THE TREATMENT OF CANCER)". https://register.epo.org/application?number=EP22758100
0 · Reply
Ge_ne_tics
Ge_ne_tics Sep. 26 at 5:13 AM
$CERO I want to see if this gets below $2 before earnings.
1 · Reply